4569
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

KYORIN Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the manufacturing and marketing of prescription drugs. The group structure includes two subsidiaries, Kyorin Remedio Co., Ltd. and Kyorin Pharmaceutical Group Factory Co., Ltd., which handle the production, testing, and distribution of pharmaceutical products. The company sources certain raw materials for its medicines from its associated company, Nihon Rikagaku Yakuhin Co., Ltd. Its business activities focus on the development and supply of therapeutic agents within the pharmaceutical sector.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage kyorin-pharm.co.jp
Sector Healthcare IR page kyorin-pharm.co.jp
Tags
pharmaceutical manufacturing, prescription drugs, drug distribution, pharmaceutical testing, Kyorin Remedio, Kyorin Pharmaceutical Group Factory, Nihon Rikagaku Yakuhin
Press page kyorin-pharm.co.jp/news

Metrics

Valuation  
Market cap ¥ 66.42B
Market cap (USD) $ 416.172M
P/E 163.91
PEG —
P/BV 0.48
P/S 0.53
P/OCF 5.45
P/FCF 7.72
Dividend yield 5.1%
Turnover / mcap —
Returns  
ROE 2.5%
ROI 2.1%
ROIC 1.7%
Profit margin 2.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -10.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 43
Quality score -22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 126.257B 130.087B 119.532B 113.27B 105.534B 102.904B 109.983B 113.62B 110.64B 115.373B 119.483B 113.121B 111.4B 107.031B
Net profit 3.448B 9.086B 5.322B 4.723B 3.932B 6.13B 6.149B 6.869B 6.574B 7.305B 13.639B 12.064B 12.025B 12.422B
Free cash flow 2.405B -2.787B -4.697B -7.397B 3.656B 65M 4.522B -4.029B 6.583B 13.741B 3.795B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.645K 1.502K 1.811K 1.704K 1.777K 1.928K 2.198K 2.161K 1.999K 2.351K 2.144K 2.874K 1.971K 2.298K
Price performance 12m 0.09 -0.17 0.06 -0.04 -0.08 -0.12 0.02 0.08 -0.15 0.1 -0.25 0.46 -0.14 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 46.2B 47.9B 52.6B 47.4B 40.4B 41.7B 47.3B 47.7B 47.6B 47.3B
↳ YoY growth -4.4% +3.6% +10.0% -9.9% -14.8% +3.0% +13.5% +0.9% -0.3% -0.5%
↳ 5y CAGR -3.5% -2.0% -0.2% -1.9% +0.1% +3.2%
Borrowings, current (JPY) 1.32B 957M 20.9B 10.4B 10.3B 10.3B 10.3B 20.3B 7.6B 2.87B
Borrowings, non-current (JPY) 3.63B 3.91B 2.63B 12.5B 11B 10.8B 10.6B 435M 20.2B 20.4B
Lease liabilities (JPY) 576M 510M 456M 679M 546M 488M 341M 211M 604M 468M
Cash and deposits (JPY) 43.6B 44.1B 32B 31.9B 27.4B 27B 19.4B 13.9B 15B 11.8B
Intangible assets (JPY) 1.2B 1.75B 3.4B 3.33B 3.79B 3.29B 5.39B 5.09B 4.76B 4.09B
Net debt (borrowings + leases - cash) (JPY) -38.1B -38.7B -7.99B -8.33B -5.56B -5.37B 1.88B 7.06B 13.4B 12B
Cash flow detail
Operating cash flow (JPY) 16.4B 10.5B 340M 7.74B 5.19B 6.35B 2.01B 1.55B 3.51B 6.38B
Purchases of property, plant and equipment (JPY) -2.21B -3.39B -2.17B -2.62B -4.07B -2.44B -6.33B -5.78B -5.7B -3.86B
Purchases of intangible assets (JPY) -437M -486M -2.2B -593M -1.06B -246M -3.08B -468M -596M -112M
Change in receivables (cash effect) (JPY) 2.1B -1.84B -4.77B 5.19B 7B -1.23B -5.62B -439M 158M 241M
Change in inventories (cash effect) (JPY) 3.29B 901M -2.11B -7.86B -5.28B -3.63B -5.81B -5.44B -12.3B -2.06B
Change in payables (cash effect) (JPY) -634M -834M 1.18B -1.66B -2.79B 3.91B 2.87B 502M 1.25B -1.08B
Dividends paid (cash effect) (JPY) -4.32B -4.33B -5.07B -4.35B -4.35B -3.77B -3.02B -3.01B -3.02B -3.3B
Interest paid (cash effect) (JPY) -29M -24M -64M -75M -68M -66M -66M -66M -173M -254M
Income taxes paid (cash effect) (JPY) -3.77B -1.66B -3.48B -1.51B -1.9B -1.25B -2.07B -2.98B -1.32B -2.87B
Operating cash flow before change in receivables (JPY) 14.3B 12.3B 5.11B 2.55B -1.81B 7.57B 7.63B 1.99B 3.35B 6.14B
Free cash flow (OCF - PPE - intangibles) (JPY) 13.7B 6.58B -4.03B 4.52B 65M 3.66B -7.4B -4.7B -2.79B 2.41B
Income detail
Research and development expense (JPY) 13.6B 14.2B 10.8B 11B 9.7B 8.9B 10.9B 8.02B 10.5B 12.1B
↳ 5y CAGR -5.7% -8.1% -5.2% -5.8% -0.9% +4.4%
Total comprehensive income (JPY) 5.32B 9.13B 5.71B 3.67B 6.28B 3.63B 3.99B 7.95B 8.57B 9.41B
Comprehensive income to owners (JPY) 5.32B 9.13B 5.71B 3.67B 6.28B 3.63B 3.99B 7.95B 8.57B 9.41B
Provision for credit losses (JPY) — — — — — — — — — 49M
Credit cost ratio (credit losses / average receivables) (%) — — — — — — — — — 0.1%
Reported Jun 26, 2017 Jun 25, 2018 Jun 24, 2019 Jun 22, 2020 Jun 21, 2021 Jun 24, 2022 Jun 26, 2023 Jun 24, 2024 Jun 19, 2025 Jun 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

KYORIN Pharmaceutical Co., Ltd. (ticker 4569), listed in Japan.

ETFs Holding KYORIN Pharmaceutical Co., Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.01% 96,600 $ 650.041K Nov 12, 2026
DFIS 0.01% 87,100 $ 586.114K Nov 12, 2026
AVDS 0.01% 5,300 $ 36.923K Nov 16, 2026
DXIV 0.01% 3,100 $ 20.861K Nov 12, 2026
DFIC 0.00% 77,201 $ 519.501K Nov 12, 2026
DFSI 0.00% 3,200 $ 21.533K Nov 12, 2026
DFAX 0.00% 27,700 $ 186.399K Nov 12, 2026
DFAI 0.00% 15,200 $ 102.284K Nov 12, 2026
AVDE 0.00% 60,400 $ 420.782K Nov 16, 2026